ACN vs CTSH
Accenture and Cognizant, both Technology
Accenture is the larger company at $79B against $21B. On trailing earnings CTSH is the cheaper of the two at a P/E of 13.5 against 14.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year CTSH returned -11% against -26% for ACN. Ryufin's sector-relative Smart Score puts ACN ahead, 8/10 against 7/10.
| Figure | ACN | CTSH |
|---|---|---|
| Last close | $181 | $62.06 |
| Market cap | $79B | $21B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 14.5 | 13.5 |
| Dividend yield | 3.3% | 2.0% |
| 1-year return | -26% | -11% |
| 5-year return | -39% | -8.3% |
| Ryufin Smart Scoresector-relative, 1–10 | 8/10 | 7/10 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Accenture
Revenue of $19B in Q3 2026, net income $2.3B. Its largest reported line is Americas, 49% of the disclosed total.
Cognizant
Revenue of $5.4B in Q1 2026, net income $662M. Its largest reported line is Health Sciences, 32% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or read the correlation.